PDUFA Date Nearing for New PSVT Drug
Source: Patrick Trucchio  (3/19/25)
If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report. More >

US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons
Source: Streetwise Reports  (3/14/25)
MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next.

More >

Biotech Stock Looks Like Is Has a Great Set Up
Source: Clive Maund  (3/12/25)
Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy. More >

Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients
Source: Jason Kolbert  (3/12/25)
Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note. More >

Biotech Advancing Pivotal Phase III Breast Cancer Trial
Source: Dr. Douglas Loe  (3/11/25)
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc. More >

With Competitor Out, New Drug Gains Edge in Chronic Cough
Source: Jason Kolbert  (3/10/25)
Phase 2b data, expected in H1/25, could support advancement of the therapeutic into late-stage development, noted a D. Boral Capital report. More >

New Drug for Major Depressive Disorder Gets Good Surprise
Source: Douglas Tsao  (3/10/25)
When a key competitor drops out, this treatment moves to top runner position; the biopharma behind it offers 1,084% upside, noted an H.C. Wainwright & Co. report. More >

Biotech Hits Critical Milestone for Cell-Pouch Bio-Hybrid Organ
Source: Streetwise Reports  (3/6/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces that the FDA has cleared its investigational new drug (IND) application for its cell pouch with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease. Find out why one analyst sees big returns coming from the stock. More >

Canadian Healthcare Co. Showcases Stable FQ424
Source: Dr. Douglas Loe  (3/6/25)
Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy. More >

Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data
Source: Streetwise Reports  (3/5/25)
Cingulate Inc.'s (CING:NASDAQ), latest Phase 3 data reinforces CTx-1301s potential as a true once-daily ADHD treatment. With an FDA meeting on the horizon, all eyes are on what's next. More >

DMT Study Set To Explore Breakthrough Potential in Stroke Recovery
Source: Streetwise Reports  (2/14/25)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.

More >

Healthcare Pioneer Expands Revolutionary Treatment Platform
Source: Streetwise Reports  (2/6/25)
Leading regenerative medicine company Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Cell Pouch technology. One analyst says it is the "most advanced encapsulation device in development." More >

Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease
Source: Douglas Lowe  (2/4/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently filed a new IND for Cell Pouch in thyroid disease. Read on to see what rating and target price Leede Financial Inc. gave this company. More >

Washington D.C. Pharma Co. Receives FDA Acceptance
Source: Dr. Ram Selvaraju  (1/28/25)
Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) recently received FDA acceptance of its request for a hearing regarding its tradipitant New Drug Application, reported an H.C. Wainwright & Co. analyst. More >

Biotech's Target Price 183.757% Higher Than Current
Source: Jason Kolbert  (1/24/25)
Read on to see why D. Boral Capital analyst Jason Kolbert gave IMUNON Inc. (IMNM:NASDAQ) a high target price. More >

AI Infrastructure Push: US$500 Billion Investment Accelerates Drug Discovery
Source: Streetwise Reports  (1/23/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) highlights the transformative potential of the US$500 billion Stargate Initiative, set to revolutionize AI-driven drug discovery. Learn how this landmark investment could redefine oncology breakthroughs.

More >

Biopharma Shares Multiple 2025 Catalysts
Source: Dr. Swayampakula Ramakanth  (1/17/25)
Innate Pharma SA's (IPHA:NASDAQ; IPH:Paris) long-term corporate strategy led to it recieving a Buy rating from H.C. Wainwright & Co. More >

Advanced AI Solutions Deliver Hope for CNS Cancer Treatment
Source: Streetwise Reports  (1/15/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) has identified AI-designed drug candidates targeting advanced cancer treatments with CNS penetration. Read more about how this breakthrough could redefine oncology innovation. More >

AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections
Source: Streetwise Reports  (1/10/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research. More >

Biotech Advances Breakthrough Cancer Treatment Results
Source: Francois Brisebois  (1/10/25)
Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note. More >

Pharma Innovator Reveals Groundbreaking Diabetes Treatment
Source: Jason Kolbert  (1/10/25)
Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share. More >

Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech
Source: Streetwise Reports  (1/6/25)
CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence. More >

Pharma Innovator Unlocks Multi-Disease Treatment Potential
Source: Jason Kolbert  (1/3/25)
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating. More >

Drug Innovator Launches Pivotal Cancer Trial Breakthrough
Source: Sean Lee  (1/3/25)
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note. More >

Miami Biopharma Sells Part of Business and Begins New Clinical Trial
Source: Dr. Yi Chen  (1/2/25)
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating. More >